Drugs / StaphVAX
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00211965 | Apr 2005 → May 2006 | staphylococcal infection | Nabi Biopharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00211991 | Apr → Jul 2005 | staphylococcal infection | Nabi Biopharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00211900 | Mar → Aug 2005 | chronic renal failure syndrome, staphylococcal infection | Nabi Biopharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00071214 | Sep 2003 → Sep 2005 | chronic renal failure syndrome, staphylococcus aureus infection | Nabi Biopharmaceuticals | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | StaphVAX | “Healthy adults recruited from one academic medical center to participate in a lot consistency trial of StaphVAX (S. aureus capsular polysaccharide 5 and 8 conjugate vaccine)...” PMID 19799842 ↗ Sep 20093“StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine” NCT00211900 ↗ “StaphVAX, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine” NCT00071214 ↗ “StaphVAX® is a bivalent S. aureus types 5 and 8 vaccine” NCT00211965 ↗ |
| Modality | Vaccine | “Bivalent Staphylococcus Aureus Glycoconjugate Vaccine” NCT00211900 ↗ |
| Route | Intramuscular | “single IM dose” NCT00211900 ↗ |